Skip To Main Content
Liying Yang on Muck Rack

Liying Yang

As seen in: Nature, Wiley Online Library, arXiv, Frontiers, MDPI, Science Magazine, Royal Society of Chemistry, BioRxiv, Cell Press, Cell Reports and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Liying

Contact Liying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Federated knowledge-guided 3D Transformer learning for bone tumor segmentation from partially annotated computed tomography data

|
By Yongan Liu, Tao Yu, Dan Su, Ming Ni, Shenyu Wang, Yuan Hong, Xinchen Li, Liying Yang, Mu Yuan Hu, Jingci Xu
| Nature Verified
Abstract Accurate 3D delineation of bone tumors and metastatic lesions from volumetric CT is essential for diagnosis, staging, radiotherapy planning, and treatment monitoring, yet manual contouring is time consuming and variable across observers. Although modern 3D CNN/Transformer segmenters achieve strong centralized performance, they typically assume pooled multi-institution data and consistent label definitions.
Open in Who Shared Issue with article?

Plasticity of extrachromosomal DNA segregation during drug adaptation

|
By Chikako Shibata, Kenichi Miyata, Marwa Akao, Kohei Kumegawa, Yumiko Maruyama, Liying Yang, Ryu-Suke Nozawa, Toru Hirota, Shingo Iwami, Shoya Iwanami, Reo Maruyama, Mana Nagamoto
| Nature Verified
Abstract Uneven segregation during mitosis is a striking feature of extrachromosomal DNA (ecDNA). Because ecDNA lacks a centromere, it is thought to segregate stochastically, generating intratumoral heterogeneity in genomic copy number. Drug treatment can readily change ecDNA copy number, enabling cells to acquire drug resistance, yet whether these changes reflect static selection of pre-existing clones or active reconfiguration under stress remains unresolved.
Open in Who Shared Issue with article?

CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma

|
By Yijia Xu, Jianfang Sun, Yuying Lu, Yujie Fan, Liying Yang, Mengying Zhang, Xin Zhe Liu, Lijuan Kong, Yanfeng Liu, Yang Su, Mingyi Zhao, Chongyang He, Yipin Xie, Jinghai Zhang
| Nature Verified
Abstract Immune checkpoint inhibitors, notably PD-1/PD-L1 monoclonal antibodies, are now used as first-line treatments for hepatocellular carcinoma (HCC) and have improved outcomes for some patients. Nevertheless, their response rate remains below 30%, largely due to HCC’s immunosuppressive microenvironment and insufficient T-cell infiltration. Strategies to address these limitations are urgently needed.
Open in Who Shared Issue with article?
See all 23 licensed articles (28 Total)